Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Perrigo resists branded, generic PPI competition: Sales of Perrigo's generic omeprazole continue to grow despite competitive pressures in the proton pump inhibitor category. Since the OTC launch of Novartis' Prevacid 24HR in November, sales of Procter & Gamble's competing Prilosec OTC dropped 6.5 percent, but sales of Perrigo's omeprazole tablet grew more than 2 percent, the private labeler said during its fiscal 2010 second-quarter earnings call Feb. 2. Dr. Reddy's generic omeprazole capsule minimally affected Perrigo's sales, because it is not displacing Perrigo's product on shelves (1"The Tan Sheet" Nov. 9, 2009). CEO Joseph Papa said Perrigo hopes to "be in the first wave" of equivalents when Sanofi-Aventis likely switches its allergy medicine Allegra to OTC in the next fiscal year. For the quarter ended Dec. 26, Allegan, Mich.-based Perrigo reported net sales of $583.2 million, up 8.6 percent, while net income more than doubled to $50.9 million

You may also be interested in...

Perrigo Strives To Stand Out Against Incoming Private Label Competition

Even as Perrigo products face the prospect of increasingly crowded segments, the company likes where it stands among private label competition

Pfizer Plans To Give Diversified Businesses Time To Grow

Pfizer plans to give its consumer products businesses "the opportunity to grow" as it integrates Wyeth into its operations, according to CEO Jeffrey Kindler

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts